119 related articles for article (PubMed ID: 36560899)
1. Comment on: Alnustone inhibits the growth of hepatocellular carcinoma via reactive oxygen species-mediated PI3K/Akt/mTOR/p70S6K axis.
Li Z
Phytother Res; 2023 Jun; 37(6):2215-2216. PubMed ID: 36560899
[No Abstract] [Full Text] [Related]
2. Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K/Akt/mTOR/p70S6K axis.
Wang L; Cheng L; Ma L; Ahmad Farooqi A; Qiao G; Zhang Y; Ye H; Liu M; Huang J; Yang X; Lin X; Cao S
Phytother Res; 2022 Jan; 36(1):525-542. PubMed ID: 34847624
[TBL] [Abstract][Full Text] [Related]
3. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
4. IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway.
Li TT; Zhu D; Mou T; Guo Z; Pu JL; Chen QS; Wei XF; Wu ZJ
Mol Immunol; 2017 Jul; 87():132-140. PubMed ID: 28433890
[TBL] [Abstract][Full Text] [Related]
5. 13-Acetoxysarcocrassolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway.
Hsu CM; Lin JJ; Su JH; Liu CI
Pharm Biol; 2022 Dec; 60(1):2276-2285. PubMed ID: 36416062
[TBL] [Abstract][Full Text] [Related]
6. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
[TBL] [Abstract][Full Text] [Related]
7. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
8. NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells.
Liu L; Chen J; Cao M; Wang J; Wang S
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1303-1314. PubMed ID: 31555866
[TBL] [Abstract][Full Text] [Related]
9. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
10. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
Longerich T
Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
[TBL] [Abstract][Full Text] [Related]
11. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
12. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
Wang H; Zhang C; Xu L; Zang K; Ning Z; Jiang F; Chi H; Zhu X; Meng Z
Oncotarget; 2016 Apr; 7(15):20193-208. PubMed ID: 26958938
[TBL] [Abstract][Full Text] [Related]
13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
14. Effects of PI3K catalytic subunit and Akt isoform deficiency on mTOR and p70S6K activation in myoblasts.
Matheny RW; Adamo ML
Biochem Biophys Res Commun; 2009 Dec; 390(2):252-7. PubMed ID: 19799871
[TBL] [Abstract][Full Text] [Related]
15. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
Li SZ; Xu F; Sun CQ; Xu P
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
Faghiri Z; Bazan NG
Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
[TBL] [Abstract][Full Text] [Related]
17. Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.
Kim SY; Hwangbo H; Kim MY; Ji SY; Lee H; Kim GY; Kwon CY; Leem SH; Hong SH; Cheong J; Choi YH
Arch Biochem Biophys; 2021 Jan; 697():108688. PubMed ID: 33227289
[TBL] [Abstract][Full Text] [Related]
18. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract][Full Text] [Related]
19. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
